Efficacy and safety of nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary procedures: a systematic review and meta-analysis

Authors

Ayesha Imran Butt, Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.
Fazila Afzal, Department of Medicine, Faisalabad Medical University, Faisalabad, Pakistan.
Sukaina Raza, Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan.
F N. Namal, Department of Medicine, Shifa International Hospital, Faisalabad, Pakistan.
Dawood Ahmed, Department of Medicine, Faisalabad Medical University, Faisalabad, Pakistan.
Hassaan Abid, Department of Medicine, IU Ball Memorial Hospital, Muncie, IN, USA.
Muhammad Hudaib, Department of Medicine, Fazaia Ruth Pfau Medical College, Karachi, Pakistan.
Zainab Safdar Sarwar, Department of Medicine, Sahiwal Medical College, Sahiwal, Pakistan.
Soha Bashir, Department of Medicine, Jinnah Hospital, Lahore, Pakistan.
Asadullah Khalid, Department of Medicine, Aziz Fatimah Medical & Dental College, Faisalabad, Pakistan.
Umer Hassan, Department of Nephrology, Shaikh Zayed Hospital, Lahore, Pakistan.
Mohammad Ebad Rehman, Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan. ebadrehman.rehman@gmail.com.Follow
Huzaifa Ahmad Cheema, Department of Cardiology, King Edward Medical University, Lahore, Pakistan. huzaifaahmadcheema@gmail.com.Follow
Ali Husnain, Department of Radiology, Northwestern University, Chicago, IL, USA.
Usama Anwar, Department of Interventional Radiology, Boston Children's Hospital, Boston, MA, USA.
Muhammad Mohid Tahir, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital Center, New York, NY, USA.
Adeel Ahmad, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Wajeeh Ur Rehman, Department of Internal Medicine, United Health Services Hospital, Johnson City, NY, USA.
Raheel Ahmed, National Heart & Lung Institute, Imperial College London, London, UK.

Document Type

Article

Publication Title

International urology and nephrology

Abstract

BACKGROUND: Contrast-induced nephropathy (CIN) is a potentially serious complication of intravenous or intra-arterial contrast administration during angiographic procedures that results in renal dysfunction. CIN can increase the risk of mortality by three-fold. This meta-analysis assesses the efficacy and safety of nicorandil for the prevention of CIN in patients undergoing percutaneous coronary intervention (PCI) or coronary angiography (CAG). METHODS: Cochrane Central Register of Controlled Trials, MEDLINE, Embase, and ClinicalTrials.gov were used to perform a thorough literature search from their inception to July 2024. Twelve randomized controlled trials (RCTs) were included. A random-effects meta-analysis was performed on RevMan and pooled estimates were presented as forest plots. The Mantel-Haenszel method was used for dichotomous outcomes and risk ratios (RRs) were calculated along with 95% confidence intervals (95% CI). RESULTS: This meta-analysis included 2787 participants (nicorandil: 1418, control: 1394). The use of nicorandil was protective against CIN (RR 0.38, 95% CI 0.29-0.50). There was no significant difference in major adverse events between the groups (RR 0.77, 95% CI 0.52-1.13, p = 0.18). Similarly, the use of nicorandil did not affect the risk of developing stroke (RR 1.05, 95% CI: 0.38-2.95), myocardial infarction (RR 0.90, 95% CI: 0.56-1.43), heart failure (RR 0.81, 95% CI: 0.39-1.68), cardiac death (RR 0.90, 95% CI: 0.28-2.88) and dialysis (RR 0.70, 95% CI: 0.11-4.44). CONCLUSION: This meta-analysis concludes that nicorandil reduces CIN incidence after PCI or CAG without significantly increasing major adverse events. However, further well-designed, large-scale RCTs are needed to strengthen the practical relevance before routine clinical use.

First Page

2181

Last Page

2194

DOI

10.1007/s11255-025-04409-1

Publication Date

7-1-2025

Identifier

39937383 (pubmed); 10.1007/s11255-025-04409-1 (doi); 10.1007/s11255-025-04409-1 (pii)

This document is currently not available here.

Share

COinS